Vatiquinone
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Inherited Mitochondrial Disease
Conditions
Inherited Mitochondrial Disease
Trial Timeline
Jun 22, 2022 → Apr 15, 2025
NCT ID
NCT05218655About Vatiquinone
Vatiquinone is a phase 3 stage product being developed by PTC Therapeutics for Inherited Mitochondrial Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05218655. Target conditions include Inherited Mitochondrial Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07159139 | Pre-clinical | Active |
| NCT05515536 | Phase 3 | Active |
| NCT05485987 | Phase 2 | Completed |
| NCT05218655 | Phase 3 | Completed |
| NCT04378075 | Phase 2/3 | Terminated |
Competing Products
4 competing products in Inherited Mitochondrial Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Umbilical cord blood transplantation with HSC835 | Novartis | Phase 1/2 | 41 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| PF-05089771 + Placebo | Pfizer | Phase 2 | 51 |
| BIIB074 + Placebo | Biogen | Phase 2 | 49 |